Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · IEX Real-Time Price · USD
5.40
-0.23 (-4.09%)
At close: Jul 19, 2024, 4:00 PM
5.28
-0.12 (-2.22%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Nanobiotix Revenue
In the year 2023, Nanobiotix had annual revenue of $40.23M with 691.80% growth.
Revenue (ttm)
$40.23M
Revenue Growth
+691.80%
P/S Ratio
6.32
Revenue / Employee
$394,412
Employees
102
Market Cap
254.40M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 40.23M | 35.15M | 691.80% |
Dec 31, 2022 | 5.08M | 2.07M | 68.91% |
Dec 31, 2021 | 3.01M | -55.46K | -1.81% |
Dec 31, 2020 | 3.06M | 208.36K | 7.30% |
Dec 31, 2019 | 2.86M | -1.14M | -28.60% |
Dec 31, 2018 | 4.00M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MultiPlan | 959.44M |
AirSculpt Technologies | 197.72M |
Nektar Therapeutics | 90.17M |
Codexis | 74.23M |
Sanara MedTech | 68.00M |
AVITA Medical | 51.50M |
Zevra Therapeutics | 28.01M |
Profound Medical | 5.33M |
NBTX News
- 5 weeks ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire
- 7 weeks ago - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update - GlobeNewsWire
- 2 months ago - Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer - GlobeNewsWire